Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19

MLA

Britton Boras, et al. “Preclinical Characterization of an Intravenous Coronavirus 3CL Protease Inhibitor for the Potential Treatment of COVID19.” Nature Communications, vol. 12, no. 1, Oct. 2021, pp. 1–17. EBSCOhost, https://doi.org/10.1038/s41467-021-26239-2.

APA

Britton Boras, Rhys M. Jones, Brandon J. Anson, Dan Arenson, Lisa Aschenbrenner, Malina A. Bakowski, Nathan Beutler, Joseph Binder, Emily Chen, Heather Eng, Holly Hammond, Jennifer Hammond, Robert E. Haupt, Robert Hoffman, Eugene P. Kadar, Rob Kania, Emi Kimoto, Melanie G. Kirkpatrick, Lorraine Lanyon, … Charlotte Allerton. (2021). Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19. Nature Communications, 12(1), 1–17. https://doi.org/10.1038/s41467-021-26239-2

Chicago

Britton Boras, Rhys M. Jones, Brandon J. Anson, Dan Arenson, Lisa Aschenbrenner, Malina A. Bakowski, Nathan Beutler, et al. 2021. “Preclinical Characterization of an Intravenous Coronavirus 3CL Protease Inhibitor for the Potential Treatment of COVID19.” Nature Communications 12 (1): 1–17. doi:10.1038/s41467-021-26239-2.